Soligenix Inc. Reports Promising Interim Results for HyBryte(TM) in Early-Stage Cutaneous T-Cell Lymphoma Treatment

Soligenix Inc. (NASDAQ: SNGX) has announced interim results from an investigator-initiated study (IIS) of its HyBryte(TM) (synthetic hypericin) program, indicating promising treatment success in early-stage cutaneous T-cell lymphoma (CTCL). The study, led by Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program, evaluates the efficacy of extended HyBryte(TM) therapy administered twice weekly for up to 54 weeks in patients with early-stage mycosis fungoides, a common type of CTCL. At the 18-week evaluation point, six out of the participants showed significant improvement, highlighting the potential of HyBryte(TM) as a viable treatment option for CTCL patients.

The lack of new FDA-approved, skin-directed therapies for CTCL in over a decade underscores the importance of Soligenix's findings. Current treatment options are limited and often come with considerable risks, making the search for safer and more effective alternatives crucial for patients suffering from early-stage CTCL. The interim results from the IIS not only demonstrate the potential of HyBryte(TM) to fill this gap but also reinforce the need for continued research and development in this area.

For more detailed information on the study and its findings, visit https://ibn.fm/IUoEe. Investors and interested parties can access the latest news and updates relating to Soligenix Inc. in the company's newsroom at https://ibn.fm/SNGX.

The implications of these interim results are significant for the medical community, patients, and investors alike. For patients, HyBryte(TM) represents a beacon of hope for a safer and more effective treatment option. For the industry, it highlights the ongoing need for innovation in the treatment of rare diseases like CTCL. And for investors, it underscores the potential of Soligenix Inc. as a key player in the biotech sector, with HyBryte(TM) poised to address a critical unmet medical need.